MedTrace Logo

Effects of SRX246 on an Experimental Model of Fear and Anxiety in Humans

NCT02922166 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2019-06-10

No results posted yet for this study

Summary

To determine the effects of SRX246 on fear and anxiety based on fear-potentiated startle in humans. Additionally, the effects of the compound on emotion recognition will be explored.

Conditions

Interventions

DRUG

SRX246

oral capsule

DRUG

Placebo

oral capsule

Sponsors & Collaborators

  • National Institute of Mental Health (NIMH)

    collaborator NIH

  • Azevan Pharmaceuticals

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-02-03
Primary Completion
2019-05-10
Completion
2019-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02922166 on ClinicalTrials.gov